Sacral neuromodulation in overactive bladder: a review and current perspectives

被引:32
作者
Sukhu, Troy [1 ]
Kennelly, Michael J. [2 ]
Kurpad, Raj [1 ]
机构
[1] Univ N Carolina, Dept Urol, 2106 Phys Off Bldg,170 Manning Dr,CB 7235, Chapel Hill, NC USA
[2] Carolinas Med Ctr, Dept Urol, Charlotte, NC 28203 USA
来源
RESEARCH AND REPORTS IN UROLOGY | 2016年 / 8卷
关键词
urge incontinence; sacral neuromodulation; overactive bladder; refractory; voiding dysfunction;
D O I
10.2147/RRU.S89544
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Overactive bladder (OAB) symptoms of urgency, frequency, and urge incontinence currently affect a substantial portion of the population, especially as age increases. Sacral neuromodulation has become a popular option for refractory OAB symptoms over the past 2 decades. Studies have demonstrated that it is an effective treatment for OAB and urge incontinence as indicated by decreased number of voids, increased bladder capacity, and fewer leakage events. In addition, the effects have proved to be durable to multiple years following implantation. These benefits come at the expense of a high rate of adverse events, although with comparable long-term cost-effectiveness to botulinum toxin A. We aimed to review the literature that demonstrates that sacral neuromodulation continues to be an efficacious treatment for refractory OAB wet and dry patients, with continuously expanding indications.
引用
收藏
页码:193 / 199
页数:7
相关论文
共 36 条
  • [1] Sacral neuromodulation: Cost considerations and clinical benefits
    Aboself, Sherif R.
    Kim, Dennis H.
    Rieder, Jocelyn M.
    Rhee, Eugene Y.
    Menefee, Shawn A.
    Kaswick, Julie R.
    Ree, Michael H.
    [J]. UROLOGY, 2007, 70 (06) : 1069 - 1073
  • [2] Describing bladder storage function: Overactive bladder syndrome and detrusor overactivity
    Abrams, P
    [J]. UROLOGY, 2003, 62 (5B) : 28 - 37
  • [3] Abrams P, 2002, NEUROUROL URODYNAM, V21, P167, DOI 10.1002/nau.10052
  • [4] Sacral neuromodulation for intractable urge incontinence: Are there factors associated with cure?
    Amundsen, CL
    Romero, AA
    Jamison, MG
    Webster, GD
    [J]. UROLOGY, 2005, 66 (04) : 746 - 750
  • [5] Cost-Effectiveness of Sacral Neuromodulation Compared to Botulinum Neurotoxin A or Continued Medical Management in Refractory Overactive Bladder
    Arlandis, Salvador
    Castro, David
    Errando, Carlos
    Fernandez, Eldiberto
    Jimenez, Miguel
    Gonzalez, Paloma
    Crespo, Carlos
    Staeuble, Funke
    Manuel Rodriguez, Jose
    Brosa, Max
    [J]. VALUE IN HEALTH, 2011, 14 (02) : 219 - 228
  • [6] Neuromodulation for overactive bladder
    Bartley, Jamie
    Gilleran, Jason
    Peters, Kenneth
    [J]. NATURE REVIEWS UROLOGY, 2013, 10 (09) : 513 - 521
  • [7] Sacral neuromodulation and Botulinum toxin A for refractory idiopathic overactive bladder: a cost-utility analysis in the perspective of Italian Healthcare System
    Bertapelle, Maria Paola
    Vottero, Mario
    Del Popolo, Giulio
    Mencarini, Marco
    Ostardo, Edoardo
    Spinelli, Michele
    Giannantoni, Antonella
    D'Ausilio, Anna
    [J]. WORLD JOURNAL OF UROLOGY, 2015, 33 (08) : 1109 - 1117
  • [8] Long-term results of sacral nerve stimulation (S3) for the treatment of neurogenic refractory urge incontinence related to detrusor hyperreflexia
    Chartier-Kastler, EJ
    Bosch, JLHR
    Perrigot, M
    Chancellor, MB
    Richard, F
    Denys, P
    [J]. JOURNAL OF UROLOGY, 2000, 164 (05) : 1476 - 1480
  • [9] Economic Burden of Urgency Urinary Incontinence in the United States: A Systematic Review
    Coyne, Karin S.
    Wein, Alan
    Nicholson, Sean
    Kvasz, Marion
    Chen, Chieh-I
    Milsom, Ian
    [J]. JOURNAL OF MANAGED CARE PHARMACY, 2014, 20 (02): : 130 - 140
  • [10] Freemantle N, EUR J HLTH EC